Abstract: Disclosed are RNA inhibitors, such as small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) specific for RND3, alternatively referred to as RhoE. Also disclosed are methods of treating subjects by administering RNA inhibitors. Further disclosed are methods of detecting potential modulators of RND3.

Abstract: Provided herein are thermal devices and single-use temperature measurement devices to predict and to monitor core body temperature in a subject, such as a patient. The devices utilize a plurality of thermal or temperature sensors disposed on a patch and insulated one from the other and a connection to a machine learning algorithm for prediction and monitoring. Also provided are systems and methods using the thermal device or temperature monitoring device and the machine learning algorithm to predict and measure core body temperature in the subject.

Abstract: The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.

Abstract: Applicants have developed novel methods and compositions for treating, preventing or ameliorating the effects plant phytopathogen infestation in plants, including of Candidatus liberibacter spp. the causal agents of citrus greening and potato zebrachip disease. Novel compositions include one or more active agents of aminocaproic acid, carbinoxamine maleate, chloroxylenol, chlorpropamide, cinoxacin, duartin, and cyclopentolate hydrochloride as well as their derivatives, or salt/acid forms thereof. Methods of preventing disease development and infestation by plant pathogens are disclosed as well as methods of making, using and producing such compositions.

Abstract: An autonomous landing system for vertical landing aircraft includes a vertical landing aircraft including a powertrain and an onboard camera, a motion-stabilized visual cue including a visual indicator, wherein the visual cue is configured to maintain a fixed orientation of the visual indicator with respect to a horizon, and an autonomous control system configured to control a position of the aircraft with respect to the visual indicator of the visual cue based on image data captured by the onboard camera.

Abstract: A microfluidic chip for modelling flow through a vein includes a body including a microchannel extending between a fluid inlet and a fluid outlet, wherein at least a portion of the microchannel is coated with endothelial cells that form vascular lumen, and a venous valve formed in the body and positioned along the microchannel, wherein the venous valve includes a pair of leaflets defining a pair of cusps of the venous valve, and a flow channel positioned between the leaflets.

Abstract: In an embodiment, the present disclosure pertains to a medical device. In some embodiments, the medical device includes a first compartmentalized microfluidic channel flanked by two microchannels and a second compartmentalized microfluidic channel. In some embodiments, the first and second compartmentalized microfluidic channels are situated vertically one to another. In some embodiments, the medical device further includes a porous membrane situated between the first and second compartmentalized microfluidic channels. In another embodiment, the present disclosure pertains to an organ-on-chip. In some embodiments, the organ-on-chip includes a top portion having three parallel microchannels. In some embodiments, the three parallel microchannels are separated by micropillars. In some embodiments, the organ-on-chip further includes a bottom portion having a fourth microchannel and a membrane between the top portion and the bottom portion.

Abstract: In an embodiment, the present disclosure pertains to a cavitation generation device that includes a dactyl plunger rotatable about an axis between an open position and a closed position and a propus socket having a channel. The propus socket is rigidly mounted below the dactyl plunger, and the dactyl plunger is received into the propus socket when the dactyl plunger is in the closed position. The cavitation generation device can also include a torsion spring that biases the dactyl plunger into contact with the propus socket. In another embodiment, the present disclosure pertains to a method of inducing a cavitation including biasing a dactyl plunger via a torsion spring, and rotating the dactyl plunger, by action of the torsion spring, into a propus socket. The propus socket includes a nozzle-shaped channel. The method further includes ejecting a socket cavity volume through the nozzle-shaped channel thereby inducing a cavitation event.

Abstract: Provided herein are methods and processes for wet-towing and installing a bucket foundation or mono-bucket for a wind turbine with or without the wind turbine mounted thereto in a body of water, such as a sea, an ocean or a lake. The methods and processes utilize at least a pair of wrap buoys secured to the bucket foundation or mono-bucket where the release thereof alters buoyancy such that the bucket foundation or mono-bucket submerges to a target site in the body of water.

Abstract: Tumor resection is commonly practiced to prevent the progression of cancer. However, there are post-surgery concerns including the formation of a void that can allow cancer cells to escape at the surgery site, which increases the risk of metastasis. To counter this challenge, an embodiment includes a polyurethane-based shape memory foam as a tissue void-filling device that can also release anti-cancer drugs. Such foams may activate at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal the tissue void and then serve as a drug-eluting device. Based on the drug composition with poly vinyl alcohol (PVA), the drug release profile from the foam may be altered depending on the application.

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

Abstract: A system for providing an indication of the presence of molecular structures in a medium is provided. The system includes a radio frequency (RF) wireless antenna, batteryless sensor, and a network analyzer. The sensor has an ultra-high frequency dipole antenna that transmits data to the RF wireless antenna and a sensing element. The sensing element is operatively coupled to the dipolar antenna and detects the presence of molecular structures. When molecular structures are detected, data indicative of the presence of the molecular structures is transmitted to a radio frequency (RF) wireless communication antenna from the dipole antenna. The network analyzer receives the data from the RF wireless antenna and analyzes the data to determine a concentration of molecular structures.

Abstract: A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.

Abstract: In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, the cation is a chiral cobalt(III) species, and a nitrogenous Brpnsted base is incorporated into counter anions of the chiral cobalt(III) species cation. In some embodiments, the bifunctional catalyst is a tricationic cobalt(III) hydrogen bond donor catalyst, and a nitrogenous Brpnsted base is incorporated into counter anions of the tricationic cobalt(III) hydrogen bond donor catalyst. In another aspect, the present disclosure pertains to a bifunctional catalyst having a smart anion with a cationic metal species. In some embodiments, the smart anion performs a specific role in a chemical reaction without the inclusion of additional external components to accomplish a same specific role in the chemical reaction.

Abstract: Threshold logic gates using flash transistors are provided. In an exemplary aspect, flash threshold logic (FTL) provides a novel circuit topology for realizing complex threshold functions. FTL cells use floating gate (flash) transistors to realize all threshold functions of a given number of variables. The use of flash transistors in the FTL cell allows a fine-grained selection of weights, which is not possible in traditional complementary metal-oxide-semiconductor (CMOS)-based threshold logic cells. Further examples include a novel approach for programming the weights of an FTL cell for a specified threshold function using a modified perceptron learning algorithm.

Abstract: A method for determining constitutive parameters of a subject material includes collecting a force sensor output from a force sensor unit for measuring reactive forces applied to a deformation tool from a subject material travelling in a predefined direction relative to the deformation tool, collecting an image sequence output from a camera unit depicting a deformation zone formed between the deformation tool and the subject material as the subject material is plastically deformed by the deformation tool, and estimating a constitutive parameter of the subject material based on the force sensor output and the image sequence output.

Abstract: In an embodiment, a method for measuring parameters of a liquid, where the method includes measuring pressure drops across a flow meter, measuring pressure upstream of the flow meter, and identifying at least one liquid parameter based, at least in part, on a correlation of a change in a multiphase flow parameter to pulse output. In an additional embodiment, a measuring apparatus for measuring parameters of a liquid, where the measuring apparatus includes an electronic control operable to measure pressure drops across the measuring apparatus, measure pressure upstream of the measuring apparatus, and correlate a change in a multiphase parameter to measured pulse output of the measuring apparatus.

Abstract: In an embodiment, the present disclosure pertains to a method for evaluation of sterility in a solution using impedance sensing. In another embodiment, the present disclosure pertains to a method for evaluation of bioburden in a solution. In a further embodiment, the present disclosure pertains to various devices for evaluation of sterility or bioburden.

Abstract: Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.

Abstract: A method of fabrication processing a pre-preg material includes applying electromagnetic heating to a composition including a fiber and a resin. The electromagnetic heating is conducted with at least one fringing field capacitor utilizing radio frequency (RF) alternating current (AC) and controlling cross-linking of the resin in the composition via the electromagnetic heating.